PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1980613
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1980613
The global orthobiologics market is witnessing substantial growth driven by the rising prevalence of bone and musculoskeletal disorders, increasing orthopedic injuries, and the adoption of regenerative medicine. The market was valued at USD 9.7 billion in 2025, projected to reach USD 10.22 billion in 2026, and is expected to grow to USD 15.06 billion by 2034, exhibiting a CAGR of 5.00% during the forecast period. North America dominated the market in 2025, capturing a 47.69% share, owing to rapid adoption of biologics for bone-related injuries, the large patient pool, and a high volume of orthopedic surgeries.
Orthobiologics are products derived from naturally occurring substances in the body, used to enhance the healing of bones, ligaments, tendons, and muscles. They are widely used in orthopedic procedures to repair bone defects and promote tissue regeneration. The increasing use of stem cell-based allografts and other biologics in orthopedic treatments is expected to further fuel market growth.
During the COVID-19 pandemic, the market experienced a temporary decline due to reduced patient visits, reallocation of healthcare resources, and supply chain disruptions. In 2020, the market revenue declined by 10.6%, but recovery began in 2021 with rising patient volumes, vaccination coverage, and resumption of orthopedic surgeries. By 2022, the market returned to pre-pandemic levels, as highlighted by Johnson & Johnson Services, Inc., which reported net sales of USD 94,943 million, including significant contributions from orthopedic products.
Market Trends
A major trend driving the market is the increased use of viscosupplements to delay total knee replacement procedures. Viscosupplements restore the rheological properties of synovial fluid, reduce pain, improve joint function, and promote cartilage regeneration. Studies indicate that treatment with hyaluronic acid injections can delay total knee replacement surgery by over one year, contributing to the growing adoption of viscosupplements.
Market Drivers
The rising incidence of orthopedic injuries, bone fractures, osteoporosis, and sports-related traumas is fueling the demand for orthobiologic products. In the U.S. alone, over 6.8 million patients seek treatment for orthopedic injuries annually. The increasing prevalence of hip and spinal fractures, along with road accidents, is also supporting market expansion.
Another driver is the launch of new orthobiologics products, including allografts, bone growth factors, and synthetic bone substitutes. For example, Royal Biologics launched MAGNUS, a DMSO-free viable cellular bone allograft in 2020, while Biocomposites received CE approval for antibiotic-eluting bone void fillers. Continuous product innovation ensures the availability of advanced solutions for bone repair, enhancing market growth.
Market Restraints
The market faces constraints due to clinical limitations of certain orthobiologics and issues associated with bone morphogenetic proteins (BMPs). Medtronic's INFUSE, a widely used BMP, has been associated with serious side effects such as infections, urinary problems, bone/nerve injury, and potential cancer risk. Adverse tissue reactions, incomplete bone formation, and soft tissue infections with other orthobiologics also limit widespread adoption.
Market Segmentation
By Product Type
By Application
By End-User
Competitive Landscape
Key players include Medtronic (Ireland), Zimmer Biomet (U.S.), DePuy Synthes (U.S.), Stryker (U.S.), Anika Therapeutics, Inc. (U.S.), SeaSpine (U.S.), Bioventus (U.S.), RTI Surgical (U.S.), MTF Biologics (U.S.), Arthrex, Inc. (U.S.), and Smith & Nephew (U.K.). Recent developments include:
Conclusion
The orthobiologics market is set to grow from USD 9.7 billion in 2025 to USD 15.06 billion by 2034, driven by the increasing prevalence of orthopedic injuries, the adoption of viscosupplements, spinal fusion procedures, and the launch of innovative biologic products. While clinical limitations of certain BMPs and bone graft substitutes may restrain growth, the rising demand for advanced, minimally invasive orthopedic treatments ensures continued market expansion.
Segmentation
By Product Type
By Application
By End-user
By Geography